4082 completed, 1219 unknown, 1199 terminated, 938 recruiting. 8717 Phase 2, 1634 Phase 1, 668 Phase 3.
Follow Lung Diseases: new trials by email Literature Review of Lung Diseases trials Research Report on Lung Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| cfMSC Stem Cell Therapy Targeting COPD clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Antigen-specific T Cells Against Lung Cancer Lung cancer-specific T cells - Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-11-02 |
| Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS Normal Saline, Centhaquine - Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Not yet recruiting | Pharmazz, Inc. | 80 | 2027-05-01 | 2026-09-17 |
| Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension 2-HOBA - Pulmonary Arterial Hypertension | Phase 2 | Not yet recruiting | Vanderbilt University Medical Center | 12 | 2027-05-01 | 2026-11-10 |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Not yet recruiting | Xemed LLC | 10 | 2027-03-01 | 2026-09-01 |
| Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia) linvemastat, Placebo - Asthma (Diagnosis), Pulmonary Function | Phase 2 | Not yet recruiting | Foresee Pharmaceuticals Co., Ltd. | 135 | 2027-03-01 | 2026-07-20 |
| An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) treprostinil SMI (treprostinil inhalation spray) - Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Not yet recruiting | United Therapeutics | 400 | 2027-03-01 | 2026-11-06 |
| Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy HDM sublingual Immunotherapy, Placebo - Asthma, Allergy | Phase 2 | Withdrawn | Boston Children's Hospital | 2027-02-01 | 2024-11-26 | |
| Little Lungs Study Calfactant, Budesonide - Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 24 | 2027-02-01 | 2026-11-02 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Pemetrexed (1), Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2027-02-01 | 2026-11-10 |
| A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer Patients Trastuzumab Deruxtecan for Injection (T-DXd) - NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer | Phase 2 | Not yet recruiting | Centre Leon Berard | 200 | 2027-02-01 | 2026-11-13 |
| Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB ID93 + GLA-SE vaccine, Placebo vaccine - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 1500 | 2027-01-31 | 2026-08-24 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO Low anticoagulation dose of argatroban and enoxaparin during ECMO, Standard anticoagulation dose of argatroban and enoxaparin during ECMO - Pneumonia, Heart Failure | Phase 2 | Not yet recruiting | University Hospital Ostrava | 200 | 2027-01-01 | 2026-04-02 |
| Continuous vs Bolus Neuromuscular Blockade Regimens in Moderate to Severe Hypoxemic Respiratory Failure and ARDS (COBRA) Neuromuscular Blocking Agent - Bolus Dosing, Neuromuscular Blocking Agent - Continuous Infusion - ARDS (Acute Respiratory Distress Syndrome) | Phase 2 | Not yet recruiting | University of Calgary | 100 | 2027-01-01 | 2026-05-14 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| Efficacy and Safety of Slow Release Dehydroepiandrosterone (DHEA ) Slow Release DHEA, Placebo - Asthma | Phase 2 | Not yet recruiting | Indiana University | 30 | 2027-01-01 | 2026-02-27 |
| Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia colistimethate sodium, 0.9% Saline - Ventilator Associated Pneumonia | Phase 2 / Phase 3 | Not yet recruiting | University Hospital Fattouma Bourguiba | 400 | 2027-01-01 | 2026-10-08 |
Showing 20 of 8717. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3136) · Lung Neoplasms (1421) · COVID-19 (1391) · Asthma (668) · Small Cell Lung Carcinoma (580) · Pulmonary Disease, Chronic Obstructive (552) · Cystic Fibrosis (252) · Coronavirus Infections (237) · Neoplasms (232) · Breast Neoplasms (214) · Respiratory Distress Syndrome (214) · Bronchiolitis Obliterans Syndrome (205) · Colorectal Neoplasms (195) · Neoplasm Metastasis (186) · Melanoma (185)
Respiratory Tract Diseases (8647) · Neoplasms by Site (4346) · Respiratory Tract Neoplasms (4316) · Thoracic Neoplasms (4308) · Neoplasms (4212) · Carcinoma, Bronchogenic (3603) · Bronchial Neoplasms (3601) · Lung Neoplasms (2915) · Infections (1924) · Respiratory Tract Infections (1797) · Pathological Conditions, Signs and Symptoms (1534) · Virus Diseases (1503) · RNA Virus Infections (1489) · Nidovirales Infections (1463)
Carboplatin (628) · Pemetrexed (438) · Cisplatin (435) · Paclitaxel (321) · Docetaxel (301) · pembrolizumab (294) · Gemcitabine (244) · Radiotherapy (214) · Erlotinib Hydrochloride (206) · Bevacizumab (194) · Nivolumab (188) · Etoposide (160) · durvalumab (142) · Drug Therapy (128) · osimertinib (125)
National Cancer Institute (NCI) (179) · GlaxoSmithKline (151) · AstraZeneca (134) · Novartis Pharmaceuticals (126) · Eli Lilly and Company (105) · Boehringer Ingelheim (96) · M.D. Anderson Cancer Center (95) · Pfizer (89) · Sun Yat-sen University (79) · Memorial Sloan Kettering Cancer Center (72) · Merck Sharp & Dohme LLC (69) · Bristol-Myers Squibb (53) · Hoffmann-La Roche (52) · National Institute of Allergy and Infectious Diseases (NIAID) (48) · Alliance for Clinical Trials in Oncology (46)
United States (3969) · China (1350) · United Kingdom (786) · Germany (782) · Spain (738) · Canada (736) · France (683) · Italy (571) · South Korea (524) · Australia (445) · Poland (421) · Belgium (418) · Netherlands (376) · Taiwan (284) · Japan (280)
Dave Singh, MD (16)
PMID 34473343, PMID 35713300, PMID 33331662, PMID 37983082, PMID 31401903, PMID 34013969, PMID 35244208, PMID 36734509, PMID 37162745, PMID 34658014, PMID 27881132, PMID 31986264, PMID 32031570, PMID 32171076, PMID 32671834, PMID 26291023, PMID 32109013, PMID 32142651, PMID 33502773, PMID 39903535, PMID 22586319, PMID 23442309, PMID 30207593, PMID 32192578, PMID 32788708, PMID 33305842, PMID 37934000, PMID 39393433, PMID 40592258, PMID 42820295, PMID 19692680, PMID 24432712, PMID 25287629, PMID 25490004, PMID 26104945, PMID 27130468, PMID 29293889, PMID 29515037, PMID 29658848, PMID 31215818, PMID 32112977, PMID 32205204, PMID 32251768, PMID 32738928, PMID 33044747, PMID 33124005, PMID 33241650, PMID 33754144, PMID 34405547, PMID 34408488
2023 (98), 2017 (62), 2018 (55), 2015 (53), 2016 (52), 2025 (52), 2014 (49), 2019 (49), 2009 (41), 2008 (32), U10CA031946 (30), U10CA032102 (28), U10CA180888 (20), U10CA021115 (15), P30CA022453 (14)